3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
7
Terminated
6
Withdrawn
1
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Prostatic Neoplasms
25
Breast Neoplasms
21
Glioblastoma
19
Carcinoma, Non-Small-Cell Lung
17
Sarcoma
11
Squamous Cell Carcinoma of Head and Neck
10
Lung Neoplasms
10
Rectal Neoplasms
8
Neoplasms
8
Hodgkin Disease
8
Head and Neck Neoplasms
8
Brain Neoplasms
8
Oropharyngeal Neoplasms
7
Glioma
7
Esophageal Squamous Cell Carcinoma
7
Esophageal Neoplasms
7
Uterine Cervical Neoplasms
6
Pancreatic Neoplasms
6
Astrocytoma
6
Triple Negative Breast Neoplasms
5
Lymphoma
5
Colorectal Neoplasms
5
Carcinoma, Squamous Cell
5
Neoplasm Metastasis
4
Melanoma
4
Medulloblastoma
4
Histiocytoma, Malignant Fibrous
4
Small Cell Lung Carcinoma
3
Rhabdomyosarcoma
3
Recurrence
3
Interventions
pembrolizumab
2
Specimen Handling
2
Nivolumab
2
Biopsy
2
talimogene laherparepvec
1
mogamulizumab
1
fludarabine phosphate
1
fludarabine
1
duvelisib
1
durvalumab
1
Whole-Body Irradiation
1
Valganciclovir
1
Therapeutics
1
Tacrolimus
1
Sirolimus
1
Radiotherapy
1
Polymerase Chain Reaction
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Methotrexate
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
Immunoglobulin G
1
Gemcitabine
1
Ganciclovir
1
Foscarnet
1
Flow Cytometry
1
Etoposide
1
Disulfides
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Sezary Syndrome
×
Radiotherapy
×
Clear all
NCT03385226
2024-12-09
PORT
University College, London
Phase 2
Active not recruiting
46 enrolled